Immunotherapy May Work Better Against Stomach Cancer When Combined with Chemo, Given Earlier
Columbia University Researchers showed in a preclinical study that combining immunotherapy with chemotherapy in the early stages of gastric cancer slowed down... Read More
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
In a recent trial, Keytruda was found to be as effective as chemotherapy in previously untreated gastric cancer patients, but it caused... Read More
First US clinical trial testing efficacy of delivering aerosolized chemotherapy
City of Hope is recruiting patients with gastric cancer for a trial of a chemotherapy spray that can be delivered straight to... Read More
Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer
A biosimilar version of Herceptin taken in combination with chemo and the immune-boosting drug Keytruda reduced tumor size in a clinical trial... Read More
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Adding Herceptin to chemotherapy in gastric cancer patients with ERBB2-positive tumors produced an 85% response rate.
Cisplatin, fluorouracil in bolus injection, and leucovorin in first-line therapy for advanced gastric cancer as an alternative to protocols with infusional fluorouracil
A chemo regimen containing fluorouracil, cisplatin and leucovorin outperformed continuous use of fluorouracil in a Brazilian study of gastric cancer patients
Manish Shah, MD, discusses avelumab’s effectiveness based on results from the JAVELIN 100 study
Manish Shah of Weill Cornell Medicine explains the results of a recent study in which gastric cancer patients given either chemo or... Read More
Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint
The new targeted drug Enhertu showed a promising response rate in a trial of patients with HER2-positive gastric cancer.
Treatment Efficacy in Metastatic Esophageal, Gastric, or Gastroesophageal Cancer According to Expression of ERCC1
The biomarker ERCC1 is of interest for predicting sensitivity to platinum-based chemo, but a recent study in the Journal of Clinical Oncology... Read More
Pfizer, Merck KGaA’s Bavencio flunks study in hard-to-treat gastric cancer
The PD-L1 inhibitor Bavencio did not outperform chemo at extending patients’ lives in a major study in gastric cancer, raising questions about... Read More
